Competition in China’s nascent market for a novel category of cutting edge cancer treatments is set to intensify, according to newly listed Innovent Biologics.
Chinese pharmaceutical companies will adopt a low price strategy on domestically-produced antibody cancer drugs, catering to millions of cancer patients who cannot afford expensive imports, said Michael Yu Dechao, co-founder and chairman of Innovent Biologics.
The development is expected to see an eventual reversal of the phenomenon of mainland patients travelling to Hong Kong to buy cheaper drugs, said Yu. In the future, he said even Hongkongers seeking access to cheaper medicines are likely to look for alternatives north of the border…
Read more : SCMP, 01.11.2018